API | metelimumab

metelimumab Report issue

Biologics mAb Experimental

AACT ChEMBL

Active Ingredient History

NOW

Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. It was dropped from further development in favour of fresolimumab, which was being developed by Genzyme as of 2006. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
metelimumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Transforming growth factor beta-1 proprotein (Homo sapiens) ^UniProt
- Transforming growth factor beta-1 proprotein (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

cat-192 | metelimumab

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Scleroderma, Systemic (Phase 1/Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 1
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue